Efficacy and safety of ranibizumab with or without panretinal laser photocoagulation versus laser photocoagulation alone in proliferative diabetic retinopathy - the PRIDE study.

Lang, Gabriele E; Stahl, Andreas; Voegeler, Jessica; Quiering, Claudia; Lorenz, Katrin; Spital, Georg; Liakopoulos, Sandra

Lang, Gabriele E; Stahl, Andreas; Voegeler, Jessica; Quiering, Claudia; Lorenz, Katrin; Spital, Georg; Liakopoulos, Sandra.

Afiliación

Lang GE; Department of Ophthalmology, University of Ulm, Ulm, Germany.
Stahl A; Eye Center, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Voegeler J; Department of Ophthalmology, University Medical Center Greifswald, Greifswald, Germany.
Quiering C; Novartis Pharma GmbH, Nuremberg, Germany.
Lorenz K; Novartis Pharma GmbH, Nuremberg, Germany.
Spital G; University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
Liakopoulos S; Eye Center at St. Franziskus-Hospital Muenster, Muenster, Germany.

Acta Ophthalmol ; 98(5): e530-e539, 2020 Aug.

Article en En | MEDLINE | ID: mdl-31808278

Palabras clave

PRIDE study; anti-VEGF therapy; panretinal laser photocoagulation; proliferative diabetic retinopathy; ranibizumab; retinal neovascularization

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Acta Ophthalmol Asunto de la revista: OFTALMOLOGIA Año: 2020 Tipo del documento: Article País de afiliación: Alemania

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google